Form 4 for DGX Quest Diagnostics
Accepted 2026-03-06 00:00:00 ET · period of report 2026-03-04 · accession 0001022079-26-000028 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-06 | 2026-03-04 | DGX | Davis J. E. | CEO, Pres, Dir | F - Tax | $204.86 | -26.4K | 142.4K | -16% | -$5.41M | |
| 2026-03-06 | 2026-03-04 | DGX | Davis J. E. | CEO, Pres, Dir | A - Grant | $204.86 | +51.7K | 168.8K | +44% | +$10.58M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-04 | F | D | 26,414 | $204.86 | 142,423 | D | — | — | (F2) Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award. |
| 2 | Common | Common Stock | 2026-03-04 | A | A | 51,652 | $204.86 | 168,837 | D | — | — | (F1) Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d). |